Fig. 3From: Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy eraFirst line in frail patients with R/M HNSCC. Weekly chemotherapy treatment is placed in the group of patients excluded from immunotherapy treatment for low PD-L1 expression (15%), for contraindications to immunotherapy treatment for uncontrolled infectious or autoimmune diseases or organ transplantation (5%) or requiring a rapid cytoreductive response (20%)Back to article page